163 related articles for article (PubMed ID: 28953386)
21. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
22. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
23. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
25. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
26. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
Escobar-Zarate D; Liu YP; Suksanpaisan L; Russell SJ; Peng KW
Cancer Gene Ther; 2013 Oct; 20(10):582-9. PubMed ID: 24030211
[TBL] [Abstract][Full Text] [Related]
27. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
28. Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1.
Lang JJ; Lv Y; Kobe B; Chen H; Tan Y; Chen L; Wang X; Mi P; Zheng X; Lin YW
J Med Chem; 2023 May; 66(10):6725-6742. PubMed ID: 37163463
[TBL] [Abstract][Full Text] [Related]
29. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Huang Y; Dong G; Li H; Liu N; Zhang W; Sheng C
J Med Chem; 2018 Jul; 61(14):6056-6074. PubMed ID: 29940115
[TBL] [Abstract][Full Text] [Related]
31. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
Desai D; Salli U; Vrana KE; Amin S
Bioorg Med Chem Lett; 2010 Mar; 20(6):2044-7. PubMed ID: 20167479
[TBL] [Abstract][Full Text] [Related]
32. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
33. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
[TBL] [Abstract][Full Text] [Related]
34. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
35. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
36. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
37. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
Zhang Y; Liang R; Chen CW; Mallano T; Dees C; Distler A; Reich A; Bergmann C; Ramming A; Gelse K; Mielenz D; Distler O; Schett G; Distler JHW
Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
Rashid S; Bibi N; Parveen Z; Shafique S
J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
[TBL] [Abstract][Full Text] [Related]
39. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
[TBL] [Abstract][Full Text] [Related]
40. Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.
Grimster NP; Anderson E; Alimzhanov M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Gero T; Harsch A; Huszar D; Kawatkar A; Kettle JG; Lyne P; Read JA; Rivard Costa C; Ruston L; Schroeder P; Shi J; Su Q; Throner S; Toader D; Vasbinder M; Woessner R; Wang H; Wu A; Ye M; Zheng W; Zinda M
J Med Chem; 2018 Jun; 61(12):5235-5244. PubMed ID: 29856615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
